513 related articles for article (PubMed ID: 30833751)
1. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.
Logtenberg MEW; Jansen JHM; Raaben M; Toebes M; Franke K; Brandsma AM; Matlung HL; Fauster A; Gomez-Eerland R; Bakker NAM; van der Schot S; Marijt KA; Verdoes M; Haanen JBAG; van den Berg JH; Neefjes J; van den Berg TK; Brummelkamp TR; Leusen JHW; Scheeren FA; Schumacher TN
Nat Med; 2019 Apr; 25(4):612-619. PubMed ID: 30833751
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
Baumann N; Rösner T; Jansen JHM; Chan C; Marie Eichholz K; Klausz K; Winterberg D; Müller K; Humpe A; Burger R; Peipp M; Schewe DM; Kellner C; Leusen JHW; Valerius T
Cancer Sci; 2021 Aug; 112(8):3029-3040. PubMed ID: 34058788
[TBL] [Abstract][Full Text] [Related]
3. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
4. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC; Shi W; Shi JJ; Lu JJ
J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
[TBL] [Abstract][Full Text] [Related]
5. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
6. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
7. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
8. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
[TBL] [Abstract][Full Text] [Related]
9. The CD47-SIRPα Immune Checkpoint.
Logtenberg MEW; Scheeren FA; Schumacher TN
Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
[TBL] [Abstract][Full Text] [Related]
10. Anti-SIRP
Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
[TBL] [Abstract][Full Text] [Related]
11. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
12. CD47/SIRPα axis: bridging innate and adaptive immunity.
van Duijn A; Van der Burg SH; Scheeren FA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
[TBL] [Abstract][Full Text] [Related]
13. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
[TBL] [Abstract][Full Text] [Related]
14. Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis.
Wu Z; Weng L; Zhang T; Tian H; Fang L; Teng H; Zhang W; Gao J; Hao Y; Li Y; Zhou H; Wang P
Cell Res; 2019 Jun; 29(6):502-505. PubMed ID: 31089204
[No Abstract] [Full Text] [Related]
15. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
17. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
[TBL] [Abstract][Full Text] [Related]
19. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
20. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]